Genetic Technologies Limited (GENE)

NASDAQ: GENE · IEX Real-Time Price · USD
2.890
+0.080 (2.85%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons.

In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes.

Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom.

Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Genetic Technologies Limited
Genetic Technologies logo
Country Australia
Founded 1989
Industry Diagnostics & Research
Sector Healthcare
Employees 60
CEO Simon Morriss

Contact Details

Address:
60-66 Hanover Street
Fitzroy, Victoria, C3 3065
Australia
Phone 011613-9415-1135
Website gtglabs.com

Stock Details

Ticker Symbol GENE
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001166272
CUSIP Number 37185R208
ISIN Number US37185R4065
SIC Code 2836

Key Executives

Name Position
Simon Morriss Chief Executive Officer
Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D. Chief Financial Officer and Company Secretary
Carl S. Stubbings BSc Chief Commercial Officer
Kevin Camilleri Chief Executive Officer of EasyDNA
Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA Consultant

Latest SEC Filings

Date Type Title
Mar 26, 2024 6-K Report of foreign issuer
Mar 25, 2024 6-K Report of foreign issuer
Mar 22, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Mar 7, 2024 6-K Report of foreign issuer
Feb 26, 2024 6-K Report of foreign issuer
Feb 20, 2024 6-K Report of foreign issuer
Feb 15, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 6-K Report of foreign issuer